Pretreatment of Acute Coronary Syndrome With Dual Antiplatelet Agents

NCT07039149 | Recruiting

• 1 other identifier: DATES.2.25/irbIH1725
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 2

Brief Summary

This is a chart review of data on use of antiplatelet (AP) medications for acute coronary syndrome in the ER. Guidelines recommend giving aspirin in the ER and a second AP agent in the cath lab. What is the outcome when the 2 agents are given n the ER?

Conditions

Major Bleeding; Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

Keywords

Dual antiplatelet therapy; Pretreatment with DAPT; Acute coronary syndrome

Outcome Measures

Primary Outcomes (1)

• Major bleeding event

  Major bleeding event is defined as any of the following: 1. bleeding causing hemodynamic compromise, 2. bleeding necessitating blood transfusion, or 3. bleeding in a closed space (intracerebral intraspinal and intraocular).

  From enrollment to the end of the study at 1 year.

Secondary Outcomes (1)

• Major adverse cardiovascular and cerebral events

  from enrollment to 1 year

Study Arms (1)

Adult patients admitted for acute coronary syndrome via the ED

Patients with ACS presenting to the ED with a planned coronary angiography for possible coronary revascularization who get aspirin in the ED will be evaluated for bleeding and major cardiovascular events when they receive a second antiplatelet agent in the ED compared with in the cath lab.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study will enroll adult patients, men and women, who present to the emergency department (ED) with acute coronary syndrome (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, and unstable angina) and who are prescribed aspirin in the ED and a second oral antiplatelet medication either in the ED (not according to recent guidelines) or upon identification of the coronary anatomy in the cath lab (based on recent guidelines). Incidence of bleeding and other cardiovascular events in these patients based in timing of administering the antiplatelet therapy.

You may qualify if:

• Adult patients
• Presenting with acute coronary syndrome (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, and unstable angina).
• Antiplatelet medication (s) prescribed during index admission to hospital.
• Willingness of the patient to be called for follow up up to 1 year after index hospitalization.

You may not qualify if:

• Non cardiac chest pain.
• No administration of antiplatelet agents during hospitalization.
• Refusal of contact for follow up.

Sponsors & Collaborators

• Jordan Collaborating Cardiology Group: lead

Study Sites (2)

Jordan University Hospital

Amman, 11180, Jordan

RECRUITING

Istishari Hospital

Amman, 11184, Jordan

NOT YET RECRUITING

MeSH Terms

Conditions

Acute Coronary Syndrome

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases

Central Study Contacts

Ayman Hammoudeh, MD, FACC

CONTACT

+96265001000; hammoudeh_ayman@yahoo.com

Laith Habahbeh, MD

CONTACT

065001000; researchcultire2020@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director, Department of Clinical Research; Director, Department of Internal Medicine

Study Record Dates

• First Submitted: June 18, 2025
• First Posted: June 26, 2025
• Study Start: August 1, 2025
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): November 1, 2026
• Last Updated: November 28, 2025

Record last verified: 2025-11

Locations

JO (2)